Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology. 8th ed. Philadelphia: Saunders Elsvier; 2007. p. 174.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114(5): 937-51.
Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25(4): 177-81.
Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 2009; 11(6): 694-704.
Cao Z, Song JH, Park YK, Maeng EJ, Nam SW, Lee JY, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 2009; 56(2): 114-8.
Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, et al. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 2006; 340(1): 256-62.
Chang FH, Tzeng DS, Lee TM, Chen TC, Hsu LS, Lung FW. Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan. Kaohsiung J Med Sci 2003; 19(4): 151-8.
Zhang J, Zhuo WL, Zheng Y, Zhang YS. Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis. Med Oncol 2009; 27(2): 540-6.
Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009; 23(3): 429-35.
Faghani M, Nikbahkt M, Salehi M, Rabbani M, Talebi A, Soleimani B, et al. Study of p53 polymorphism at codon 72 in patients of breast cancer in Isfahan. J Isfahan Med 2007; 25(84): 679-85.
Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible assosiations with breast cancer and lung adenocarcinoma. Saudi Med J 2004; 25(11): 1568-73.
Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003; 10(4): 430-5.
Dastjerdi MN. TP53 codon 72 polymorphism and P53 protein expression in colorectal cancer specimen in Isfahan. Acta Med Iran 2011; 49(2): 71-7.
TP53 codon 72 heterozygosity may promote microsatellite instability in sporadic colorectal cancer. Yakhteh 2010; 12(1): 25-32 .
Nikbahkt Dastjerdi M, Salehi M, Mohajeri MR, Morsali F, Mirmohammad Sadeghi H, Esfandiary E. Evidence for an association of TP53 codon 72 polymorphism with sporadic colorectal cancer risk in Isfahan. JRMS 2008; 13(6): 317-23.
Nikbakht Dastjerdi M, Hasanzadeh M, Talebi A, Akbari M. Investigation of p53 codon 72 polymorphism in patients with nonmelanoma skin cancers in Isfahan. J Isfahan Med School 2011; 29(141): 679-84. [Article in Farsi]
Xiong X, Wang M, Wang L, Liu J, Zhao X, Tian Z, et al. Risk of MDM2 SNP309 alone or in combination with the p53 codon 72 polymorphism in acute myeloid leukemia. Leuk Res 2009; 33(11): 1454-8.
Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89(7): 868-9.
Majid A, Richards T, Dusanjh P, Kennedy DB, Miall F, Gesk S, et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol 2011; 153(4): 533-5.
Hamú CS, Oliveira MVP, Silva AMTC, Silva CC, Cruz AD. Codon 72 polymorphism of the TP53 gene in patients suspected to have CML. Rev Bras Hematol Hemoter 2007; 29(4): 346-50. [Article in Portuguese]
Nikbakht Dastjerdi M, Eslami B, Abutorabi R. Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan. Iran J Reprod Med 2013; 11(6): 473-8.
Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF Jr, Herrero R, Bratti MC, et al. p53 polymorphism and risk of cervical cancer. Nature 1998; 396(6711): 531-2.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393(6682): 229-31.
Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999; 354(9174): 218-9.
Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev 2000; 9(2): 113-8.
Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature 1998; 396(6711): 530-1.
Josefsson AM, Magnusson PK, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO, et al. p53 polymorphism and risk of cervical cancer.
Nature 1998; 396(6711): 531.
Lanham S, Campbell I, Watt P, Gornall R. p53 polymorphism and risk of cervical cancer. Lancet 1998; 352(9140): 1631.
Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000; 87(4): 528-33.
Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002; 179(2): 175-83.
Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8(10): 843-54.
Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44(5): 266-70.
Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res 2003; 36(2): 279-83.
Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11(2): 289-92.
Lu XM, Zhang YM, Lin RY, Liang XH, Zhang YL, Wang X, et al. p53 polymorphism in human papillomavirus-associated Kazakh’s esophageal cancer in Xinjiang, China. World J Gastroenterol 2004; 10(19): 2775-8.
Sci J Iran Blood Transfus Organ 2015; 12(1): 23-31
Original Article
Investigation of p53 codon 72 polymorphism in patients with acute myeloid leukemia in Iran
Nikbakht Dastjerdi M.1
1School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract Background and Objectives
A common polymorphism at codon 72 in the p53 gene has been associated with the increased risk for lung, oral, prostate, breast and colorectal cancers. We studied this polymorphism in acute myeloid leukemia specimen from Alzahra Hospital in Isfahan city.
Materials and Methods
In the present case-control study, 59 whole blood specimen from normal people and 59 acutemyeloid leukemia specimen were analyzed. p53 codon 72 genotypes were identified using allele-specificPCR. Chi-square test was used for the comparison of the frequency distribution of three genotypes of codon 72 in cases and control specimen.
Results
Resulting PCR products were either 177bp for proline allele or 141bp for arginine allele. The genotype distribution for p53 polymorphism showed 11.9%, 81.4%, and 6.8% for the Arg/Arg, Arg/Pro, and Pro/Pro genotypes in control samples and 33.9%, 61%, and 5.1% in acute myeloid leukemia specimen, respectively. The differences in the distribution of p53 codon 72 polymorphism between the cases and controls were statistically significant (p = 0.04).
Conclusions
Deferasirox is relatively more effective than deferoxamine in reducing iron content of the liver and heart. Moreover, deferasirox is more effective in reducing cardiac iron content relative to liver iron content.
Correspondence: Nikbakht Dastjerdi M., PhD of Anatomy. Associate Professor of School of Medicine, Isfahan University of Medical Sciences.
Postal Code: 81744176, Isfahan, Iran. Tel: (+98311) 37922403; Fax: (+98311) 37922517
E-mail: nikbakht@med.mui.ac.ir
Nikbakht Dastjerdi M. Investigation of p53 codon 72 polymorphism in patients with acute myeloid leukemia in Iran. Sci J Iran Blood Transfus Organ 2015; 12 (1) :23-13 URL: http://bloodjournal.ir/article-1-860-en.html